KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $1.4 billion.

  • Recursion Pharmaceuticals' Liabilities and Shareholders Equity rose 9263.98% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year increase of 10102.81%. This contributed to the annual value of $1.4 billion for FY2024, which is 12160.02% up from last year.
  • Recursion Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.4 billion in Q3 2025, which was up 9263.98% from $1.3 billion recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $1.4 billion for Q4 2024, and its period low was $271.9 million during Q1 2021.
  • For the 5-year period, Recursion Pharmaceuticals' Liabilities and Shareholders Equity averaged around $792.3 million, with its median value being $672.5 million (2022).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Liabilities and Shareholders Equity soared by 17002.68% in 2022, and later tumbled by 1456.49% in 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $610.3 million in 2021, then increased by 14.9% to $701.3 million in 2022, then dropped by 6.79% to $653.7 million in 2023, then surged by 121.6% to $1.4 billion in 2024, then fell by 3.39% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.